Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.S. FDA Lifts Clinical Holds On Anemia Compounds Under Development By Astellas/FibroGen

This article was originally published in PharmAsia News

Executive Summary

FDA has deemed FibroGen's response to a clinical hold on two oral anemia therapy candidates complete, allowing Phase II trials of the compounds to resume, FibroGen's development partner, Astellas Pharma, announced April 2
Advertisement

Related Content

AstraZeneca To Share FibroGen’s Anemia Compound With Astellas, But Will Hoard China For Itself
Astellas Taps Pfizer Exec To Run New Global Development HQ
Astellas Taps Pfizer Exec To Run New Global Development HQ
Advertisement
UsernamePublicRestriction

Register

SC068361

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel